NCT00050336

A Phase 3 Randomized Study of Lonafarnib in Combination With Paclitaxel and Carboplatin vs. Placebo in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer

Terminated Phase 3 Last updated 26 August 2015

What this trial tests

Phase 3 trial testing Lonafarnib (SARASAR) in Carcinoma, Non-small-cell Lung in 702 participants. Terminated before completion.

Timeline

1 December 2002

Primary endpoint
1 February 2004

1 March 2004

Quick facts

Lead sponsor	Merck Sharp & Dohme LLC
Phase	Phase 3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	702
Start date	1 December 2002
Primary completion	1 February 2004
Estimated completion	1 March 2004

Drugs / interventions tested

• Lonafarnib (SARASAR) — full drug profile →

Conditions studied

• Carcinoma, Non-small-cell Lung — all drugs for Carcinoma, Non-small-cell Lung →
• Metastases, Neoplasm — all drugs for Metastases, Neoplasm →

Sponsor

Merck Sharp & Dohme LLC — full company profile →

Who can join

18 and older, any sex, with Carcinoma, Non-small-cell Lung or Metastases, Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the overall survival of patients diagnosed with Stage 3b or 4 non-small cell lung cancer (NSCLC) treated with an oral Farnesyl Protein Transferase Inhibitor (Lonafarnib/SCH 66336) in combination with paclitaxel and carboplatin with that of patients treated with placebo in combination with paclitaxel and carboplatin.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

1. Tumor biomarkers for diagnosis, prognosis and targeted therapy.
   Zhou Y, Tao L, Qiu J, Xu J, et al · · 2024 · cited 379× · PMID 38763973 · DOI 10.1038/s41392-024-01823-2
2. Insights into the post-translational modification and its emerging role in shaping the tumor microenvironment.
   Li W, Li F, Zhang X, Lin HK, et al · · 2021 · cited 147× · PMID 34924561 · DOI 10.1038/s41392-021-00825-8
3. Systematic and comprehensive insights into HIF-1 stabilization under normoxic conditions: implications for cellular adaptation and therapeutic strategies in cancer.
   Zhang J, Yao M, Xia S, Zeng F, et al · · 2025 · cited 63× · PMID 39757165 · DOI 10.1186/s11658-024-00682-7
4. Protein lipidation in health and disease: molecular basis, physiological function and pathological implication.
   Yuan Y, Li P, Li J, Zhao Q, et al · · 2024 · cited 56× · PMID 38485938 · DOI 10.1038/s41392-024-01759-7
5. A metabolic modeling approach reveals promising therapeutic targets and antiviral drugs to combat COVID-19.
   Santos-Beneit F, Raškevičius V, Skeberdis VA, Bordel S. · · 2021 · cited 33× · PMID 34099831 · DOI 10.1038/s41598-021-91526-3
6. The complex journey of targeting RAS in oncology.
   Wasiak K, Ciunowicz D, Kierasińska-Kałka A, Węgierska M, et al · · 2025 · cited 7× · PMID 40597785 · DOI 10.1186/s12885-025-14033-y